Pulse Biosciences (NASDAQ:PLSE – Get Free Report) and NexGel (NASDAQ:NXGL – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.
Profitability
This table compares Pulse Biosciences and NexGel’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pulse Biosciences | -6,755.78% | -94.42% | -79.96% |
| NexGel | -51.26% | -121.18% | -41.15% |
Analyst Ratings
This is a summary of recent ratings and price targets for Pulse Biosciences and NexGel, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pulse Biosciences | 1 | 0 | 5 | 1 | 2.86 |
| NexGel | 1 | 2 | 0 | 0 | 1.67 |
Pulse Biosciences presently has a consensus target price of $60.20, suggesting a potential upside of 32.05%. NexGel has a consensus target price of $40.00, suggesting a potential upside of 672.20%. Given NexGel’s higher possible upside, analysts plainly believe NexGel is more favorable than Pulse Biosciences.
Institutional and Insider Ownership
77.0% of Pulse Biosciences shares are owned by institutional investors. Comparatively, 2.2% of NexGel shares are owned by institutional investors. 74.0% of Pulse Biosciences shares are owned by insiders. Comparatively, 19.8% of NexGel shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Pulse Biosciences and NexGel”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pulse Biosciences | $350,000.00 | 9,222.21 | -$72.78 million | ($1.18) | -38.64 |
| NexGel | $11.42 million | 0.22 | -$3.00 million | ($0.71) | -7.30 |
NexGel has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than NexGel, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Pulse Biosciences has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500. Comparatively, NexGel has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500.
Summary
Pulse Biosciences beats NexGel on 8 of the 14 factors compared between the two stocks.
About Pulse Biosciences
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
About NexGel
NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
